Article

Daily Medication Pearl: Diroximel Fumarate (Vumerity)

Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.

Medication Pearl of the Day: Diroximel fumarate (Vumerity)

Indication: Diroximel fumarate (Vumerity)is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Insight:

  • Dosing: Starting dose 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days 462 mg administered as two 231 mg capsules twice a day, orally.
  • Dosage forms: Delayed-release capsules 231 mg.
  • Adverse events: Most common adverse reactions for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.
  • Mechanism of action: MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
  • Manufacturer: Biogen

Sources:

vumerity-prescribing-information.pdf

vumerity image - Google Search

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com